Genmab describes Darzalex-fueled pipeline

Genmab A/S (CSE:GEN; OTCBB:GMXAY) hopes to put at least four new candidates into the clinic over the next four years using revenue from newly approved multiple myeloma (MM) drug Darzalex daratumumab. The company also presented data from a Phase I/II study of Darzalex plus Revlimid lenalidomide